B
Benoit Ledoussal
Publications - 3
Citations - 155
Benoit Ledoussal is an academic researcher. The author has contributed to research in topics: Integrase & Infectivity. The author has an hindex of 3, co-authored 3 publications receiving 126 citations.
Papers
More filters
Journal ArticleDOI
Dual inhibition of HIV-1 replication by integrase-LEDGF allosteric inhibitors is predominant at the post-integration stage.
Erwann Le Rouzic,Damien Bonnard,Sophie Chasset,Jean-Michel Bruneau,Francis Chevreuil,Frédéric Le Strat,Juliette Nguyen,Roxane Beauvoir,Céline Amadori,Julie Brias,Sophie Vomscheid,Sylvia Eiler,Nicolas Levy,Olivier Delelis,Eric Deprez,Ali Saïb,Alessia Zamborlini,Stéphane Emiliani,Marc Ruff,Benoit Ledoussal,François Moreau,Richard Benarous +21 more
TL;DR: The crystal structure of Mut101 in complex with IN is determined and it is shown that the compound binds to the LEDGF-binding pocket, promoting conformational changes of IN which explain at the atomic level the allosteric effect of the IN/LEDGF interaction inhibitor on IN functions.
Journal ArticleDOI
Structural Basis for E. coli Penicillin Binding Protein (PBP) 2 Inhibition, a Platform for Drug Design.
Nicolas Levy,Jean-Michel Bruneau,E. Le Rouzic,Damien Bonnard,F. Le Strat,Audrey Caravano,Francis Chevreuil,Julien Barbion,Sophie Chasset,Benoit Ledoussal,François Moreau,Marc Ruff +11 more
TL;DR: Examination of the structure of the E. coli PBP2 in its Apo form and upon its reaction with 2 diazabicyclo derivatives, avibactam and CPD4, a new potent P BP2 inhibitor shows that unlike avibactsam, C PD4 can perform a hydrophobic stacking on Trp370 in the active site of E. bacteria.
Journal ArticleDOI
The HIV-1 integrase-LEDGF allosteric inhibitor MUT-A: resistance profile, impairment of virus maturation and infectivity but without influence on RNA packaging or virus immunoreactivity
Céline Amadori,Yme U. van der Velden,Damien Bonnard,Igor Orlov,Nikki van Bel,Erwann Le Rouzic,Laia Miralles,Julie Brias,Francis Chevreuil,Danièle Spehner,Sophie Chasset,Benoit Ledoussal,Luzia Mayr,François Moreau,Felipe García,José M. Gatell,Alessia Zamborlini,Stéphane Emiliani,Stéphane Emiliani,Stéphane Emiliani,Marc Ruff,Bruno P. Klaholz,Christiane Moog,Ben Berkhout,Montserrat Plana,Richard Benarous +25 more
TL;DR: Although strongly defective in infectivity, HIV-1 virions produced in the presence of the MUT-A INLAI have a normal protein and genomic RNA content as well as B and T cell immunoreactivities comparable to non-treated HIV-2 and inactivated viruses might form an attractive new approach in vaccine research.